



**Department of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

**September 16, 2014 6:00 – 8:15 p.m.**

**\*\*\* Please note new times \*\*\***

- 1. Executive Session** **6:00 - 6:15**
  - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
  
- 2. Introductions and Approval of DUR Board Minutes** **6:15 - 6:20**  
(Public Comment Prior to Board Action)
  
- 3. DVHA Pharmacy Administration Updates** **6:20 - 6:30**
  - Updates
  
- 4. Medical Director Update** **6:30 - 6:35**
  - Clinical Programs Update
  - Prescriber Comments
  
- 5. Follow-up Items from Previous Meetings** **6:35 – 6:50**
  - Muscle Relaxants
  - Benzodiazepines
  
- 6. RetroDUR/DUR** **6:50 – 7:00**
  - Zolpidem Updated Dose Recommendations QA: Zolpidem Dosing Post FDA Safety Warning
  
- 7. Clinical Update: Drug Reviews** **7:00 – 7:40**  
(Public comment prior to Board action)

**Abbreviated New Drug Reviews**

- Desvenlafax ER (desvenlafaxine fumarate) Extended Release Oral Tablet

**Full New Drug Reviews**

- Duavee<sup>®</sup> (bazedoxifene/conjugated estrogens) Oral Tablet
- Hetlioz<sup>®</sup> (tasimelteon) Oral Capsule
- Orenitram<sup>®</sup> (treprostinil) Extended Release Oral Tablet
- Otezla<sup>®</sup> (apremilast) Oral Tablet

- 8. Therapeutic Drug Classes – Periodic Review** **7:40 – 7:40**  
(Public comment prior to Board action)
- None
- 9. Clinical Update: New/Updated Clinical Guidelines** **7:40 – 7:40**  
(Public comment prior to Board action)
- Synagis<sup>®</sup> (see below)
- 10. New Managed Therapeutic Drug Classes** **7:40 – 7:40**  
(Public comment prior to Board action)
- None
- 11. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **7:40 – 8:15**  
(Public comment prior to Board action)
- Pulmonary: Synagis<sup>®</sup>: New AAP Guidelines
- Updates for 1/1/2015**
- Anti-emetics: NK1 Antagonists
  - Anti-infectives: Antibiotics: Cephalosporins
  - Cystic Fibrosis: Medications
  - Dermatological Agents: Scabicides and Pediculocides
  - Gastrointestinal: Inflammatory Bowel Agents (Oral/Rectal)
  - Hepatitis C Agents
  - Otic: Anti-infectives
  - Testosterone: Topical
  - Vitamins: Prenatal Vitamins
- 12. General Announcements** **8:15– 8:15**  
**Selected FDA Safety Alerts**
- None
- 13. Adjourn** **8:15**